Compare LBRX & RSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRX | RSI |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2025 | 2020 |
| Metric | LBRX | RSI |
|---|---|---|
| Price | $44.89 | $12.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $58.00 | $23.21 |
| AVG Volume (30 Days) | 372.4K | ★ 5.0M |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 98.22 | ★ 933.33 |
| EPS | N/A | ★ 0.28 |
| Revenue | N/A | ★ $1,134,428,000.00 |
| Revenue This Year | N/A | $38.37 |
| Revenue Next Year | N/A | $14.29 |
| P/E Ratio | ★ N/A | $43.73 |
| Revenue Growth | N/A | ★ 22.76 |
| 52 Week Low | $14.32 | $11.27 |
| 52 Week High | $50.16 | $34.53 |
| Indicator | LBRX | RSI |
|---|---|---|
| Relative Strength Index (RSI) | 64.68 | 22.95 |
| Support Level | $27.40 | N/A |
| Resistance Level | $49.74 | $22.46 |
| Average True Range (ATR) | 2.77 | 1.04 |
| MACD | 0.61 | -0.10 |
| Stochastic Oscillator | 90.82 | 14.47 |
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
Rush Street Interactive Inc is an online gaming and entertainment company that focuses on online casinos and online sports betting in the U.S. and Latin American markets. It provides customers with an array of gaming offerings such as real-money online casinos, online sports betting, and retail sports betting, as well as social gaming, which involves free-to-play games that use virtual credits that can be earned or purchased. The company generates revenue by offering online casinos, online sports betting, and social gaming directly to the end customer through its websites or apps. The company generates revenue through business-to-consumer (B2C) and business-to-business (B2B) models.